Inflammatix has won a $1.7 million grant from the U.S. National Institutes of Health (NIH) that it plans to use to develop a rapid diagnostic test that will identify immune subtypes of sepsis.
Using host immune mRNA signatures, the company has identified three sepsis subtypes ("endotypes"). The NIH award will allow Inflammatix to further investigate each endotype's signature and to develop a rapid, 30-minute test to identify them, it said.
